|
Variable
|
All, n (%)
|
pCR, n (%)
|
Non-pCR, n (%)
|
P value
|
|---|
|
Patient age (years)
|
48.7 ± 10.7
|
45.0 ± 10.4
|
49.9 ± 10.6
|
0.169
|
|
Tumor size (mm3)*
|
11.6 ± 11.2
|
11.7 ± 11.7
|
11.3 ± 10.1
|
0.936
|
|
Histological type*
| | | | |
|
Invasive
|
47 (94.0)
|
11 (91.7)
|
36 (94.7)
| |
|
Other
|
3 (6.0)
|
1 (8.3)
|
2 (5.3)
|
0.696
|
|
Histologic grade*
| | | | |
|
1–2
|
34 (68.0)
|
11 (91.7)
|
23 (60.5)
| |
|
3
|
16 (32.0)
|
1 (8.3)
|
15 (24.0)
|
0.060
|
|
Clinical stage*
| | | | |
|
II
|
18 (36.0)
|
9 (75.0)
|
9 (76.0)
| |
|
III
|
32 (64.0)
|
3 (25.0)
|
29 (71.0)
|
0.001
|
|
T stage*
| | | | |
|
T1–T2
|
19 (38.0)
|
9 (75.0)
|
10 (26.3)
| |
|
T3–T4
|
31 (62.0)
|
3 (25.0)
|
28 (73.7)
|
0.002
|
|
N stage*
| | | | |
|
N0
|
4 (8.0)
|
1 (8.3)
|
3 (7.9)
| |
|
N1–3
|
46 (92.0)
|
11 (91.7)
|
35 (92.1)
|
0.961
|
|
Lymph node size*
| | | | |
|
≤ 1.0 cm
|
29 (58.0)
|
7 (58.3)
|
22 (57.9)
| |
|
> 1.0 cm
|
21 (42.0)
|
5 (41.7)
|
16 (42.1)
|
0.979
|
|
NAC regimen
| | | | |
|
EC
|
16 (32.0)
|
4 (33.3)
|
12 (31.6)
| |
|
EC-T(H)
|
24 (48.0)
|
6 (50.0)
|
18 (47.4)
| |
|
TEC or other
|
10 (20.0)
|
2 (16.7)
|
8
(21.1)
|
0.947
|
|
AC cycle
| | | | |
|
1–4
|
16 (32.0)
|
3 (25.0)
|
13 (34.2)
| |
|
5–8
|
34 (68.0)
|
9 (75.0)
|
25 (65.8)
|
0.551
|
|
CEA level*
| | | | |
|
Normal
|
45 (90.0)
|
11 (91.7)
|
34 (89.5)
| |
|
Abnormal
|
5 (10.0)
|
1 (8.3)
|
4 (10.5)
|
0.654
|
|
CA125 level*
| | | | |
|
Normal
|
46 (92.0)
|
11 (91.7)
|
35 (92.1)
| |
|
Abnormal
|
4 (8.0)
|
1 (8.3)
|
3 (7.9)
|
0.961
|
|
CA153 level*
| | | | |
|
Normal
|
45 (90.0)
|
10 (83.3)
|
35 (92.1)
| |
|
Abnormal
|
5 (10.0)
|
2 (16.7)
|
3 (7.9)
|
0.377
|
|
Breast cancer subtype
| | | | |
|
TNBC
|
12 (24.0)
|
4 (33.3)
|
8 (21.1)
| |
|
Her-2 positive
|
10 (20.0)
|
2 (16.7)
|
8 (21.1)
| |
|
Luminal A(B)
|
28 (56.0)
|
6 (50.0)
|
22 (57.9)
|
0.683
|
|
Ki-67 status
| | | | |
|
≤ 20%
|
15 (30.0)
|
2 (16.7)
|
13 (34.2)
| |
|
> 20%
|
35 (70.0)
|
10 (83.3)
|
25 (65.8)
|
0.248
|
- NAC neoadjuvant chemotherapy, TNBC triple-negative breast cancer, EC epirubicin plus cyclophosphamide, TH docetaxel plus Herceptin, TEC docetaxel, epirubicin plus cyclophosphamide
- *Data are measured at baseline. The data of patient age and tumor size are mean ± standard deviation
